Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diastolic Hypertension Clear all
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
46
States / cities
Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 23, 2026, 12:54 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Comparison Fetal Hemodynamic Measurements Antihypertensive Versus Control

NCT00759278
View directory record Official record
Conditions
Hypertension, Pregnancy
Interventions
ultrasound evaluation in pregnancy
Procedure
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

NCT01961323
View directory record Official record
Conditions
Hypertension, Left Ventricular Diastolic Dysfunction
Interventions
Nebivolol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 23, 2026, 12:54 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jul 23, 2026, 12:54 AM EDT
Terminated Not applicable Interventional

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

NCT04467879
View directory record Official record
Conditions
Hypertension, Systolic
Interventions
Zona Plus Device, Control Device
Device
Lead sponsor
Zona Health, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
St Louis, Missouri • Charlotte, North Carolina • Goldsboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jul 23, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Results available

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

NCT02053246
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Nebivolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Jul 23, 2026, 12:54 AM EDT
Withdrawn Phase 2 Interventional

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

NCT07221513
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions
JK07
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

NCT02589977
View directory record Official record
Conditions
Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
Interventions
regadenoson
Drug
Lead sponsor
Marvin W. Kronenberg, M.D.
Other
Eligibility
50 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

NCT06343129
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jul 23, 2026, 12:54 AM EDT
Active, not recruiting Phase 2 Interventional

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT05888233
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Interventions
Allopurinol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

NCT00797316
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Jul 23, 2026, 12:54 AM EDT
Completed No phase listed Observational

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

NCT02275793
View directory record Official record
Conditions
Diastolic Heart Failure, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth

NCT00508612
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Williams LifeSkills Stress and Anger Management Workshop, High school classes
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
14 Years to 18 Years
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Augusta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

NCT00170924
View directory record Official record
Conditions
Diastolic Dysfunction, Hypertension
Interventions
Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years and older
Enrollment
317 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 23, 2026, 12:54 AM EDT
Completed No phase listed Observational

Heart Disease in Sickle Cell Anemia

NCT00113152
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

NCT02133352
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RTN-001, Matching placebo control
Drug
Lead sponsor
Retension Pharmaceuticals. Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Tucson, Arizona • San Jose, California • West Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
View directory record Official record
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Not applicable Interventional Results available

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

NCT01056718
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mercy Research
Other
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 23, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 23, 2026, 12:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

NCT01942395
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (DASH/SRD), Control Diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 23, 2026, 12:54 AM EDT